Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 185 million in issue proceeds.
Vinge has advised Bergs Timber AB (publ) in connection with the transfer of the sawmills in Orrefors, Vimmerby, Mörlunda and the assets at the already discontinued operations at Gransjö.
The board of directors of Medicover has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Medicover will raise proceeds of SEK 1.5 billion, before issue costs.
Vinge has advised VNV Global in connection with the process of changing the group’s domicile from Bermuda to Sweden (the “Redomestication”). The Redomestication is carried out by way of a scheme of arrangement under Bermuda law, whereby Swedish Depository Receipts in VNV Global Ltd. will be exchanged for shares in the Swedish group entity VNV Global AB (publ) that, following the Redomestication, will constitute the new parent company of the group. The shares of VNV Global AB (publ) will be listed on the main market of Nasdaq Stockholm.
Vinge has advised Nanoform Finland Plc (“Nanoform”) in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden.
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 1,414 million, before issue costs.
Vinge has advised Equinor ASA in connection with a sale of shares in Lundin Energy AB (publ) through an accelerated bookbuilding process. In total, approximately 14,000,000 shares were placed at a price of SEK 235 per share, corresponding to a total value of approximately SEK 3.3 billion.
Vinge has advised CELLINK AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm Main Market, with an estimated market capitalisation of approximately SEK 4.1 billion. The prospectus was published on 15 April 2020 and the trading on Nasdaq Stockholm commenced on 20 April 2020.
Vinge has advised Isofol Medical AB (publ), First North Growth Market Premier, in connection with its rights issue in the total amount of MSEK 150 and, conditional upon oversubscription in respect of the rights issue, a directed new issue of shares of a total amount of MSEK 30.
